hero image

Biogen Announces Publication of BIIB080 Phase 1b Data in Nature Medicine

April 28, 2023 Company Statements

Nature Medicine has published a manuscript detailing promising results from Biogen’s multiple ascending dose Phase 1b trial, which evaluated the safety, pharmacokinetics and target engagement of Biogen’s BIIB080 (MAPT ASO), an investigational antisense oligonucleotide targeting tau mRNA in early-stage Alzheimer’s disease (AD).

These early stage data support our commitment to building on a deep expertise in Alzheimer’s Disease by advancing Biogen’s industry-leading Alzheimer's pipeline across therapeutic modalities and molecular targets.

A link to the manuscript is provided here: https://www.nature.com/articles/s41591-023-02326-3

Currently, the Phase 2 CELIA study of BIIB080 (NCT05399888) is in progress and recruiting participants in the United States.

In December 2019, Biogen exercised a license option with Ionis and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB080 (tau ASO).

++

 

 

thumb
June 1, 2023
Biogen Announces Webcast of Annual Meeting of Stockholders

Cambridge, Mass. – June 1, 2023 – Biogen Inc. (Nasdaq: BIIB) announced today that the webcast of the Company's 2023 Annual Meeting of Stockholders will be held on Wednesday, June 14, 2023, at 9:00 a.m. Eastern Time.  A live audio webcast of the meeting will be available on the Investor Relations

thumb
May 23, 2023
Biogen to Participate in the Jefferies Healthcare Conference

Cambridge, MA, - -  Biogen Inc.   (Nasdaq: BIIB) announced today that Michael McDonnell, Chief Financial Officer, and Priya Singhal, M.D., M.P.H., Head of Development, will participate in the Jefferies Healthcare Conference. The webcast will be live on Wednesday, June 7, 2023, at 11:30 a.m.